Shanghai Chengge Biotech Secures Over RMB 100 Million Led by Jinhe Capital to Redefine the Multi-Billion-Dollar Microbiome Therapeutics Landscape with Precision Fecal Microbiota Transplantation

Amid the wave of precision medicine, an emerging field targeting the human “second genome”—the gut microbiota—is unleashing remarkable energy.

Recently,Shanghai TreatGut Biotechnology Co., Ltd. (“TreatGut”), a leading enterprise in China’s medical microbiome sector, announced the successful closing of its strategic investment round. The lead investor was Kinghall Ventures, a market-oriented investment firm deeply entrenched in the healthcare industry, with Xiahe Capital serving as the financial advisor to the lead investor.

Modern lifestyles, antibiotic misuse, and other factors have led to a surge in the global population suffering from gut microbiota dysbiosis. Extensive research indicates that disruptions in the gut microbiome are closely associated with digestive disorders (such as Clostridioides difficile infection and inflammatory bowel disease), metabolic diseases (such as obesity and diabetes), neurological conditions (such as autism spectrum disorder and depression), and even responses to tumor immunotherapy. However, conventional drugs often struggle to precisely modulate the complex microbial networks, underscoring an urgent need for revolutionary therapeutic interventions.

The core competitiveness of TreatGut lies in its constructedThe World's First Precision Microbiota Transplantation Therapy (PMTT) PlatformIntegrated Platform. This is not merely “fecal microbiota transplantation,” but a comprehensive solution based on in-depth microbiome analysis, precise matching, standardized preparation, precision transplantation, and intelligent delivery:

• “Precision Screening” Sample Bank:Establish a rigorously screened, high-quality healthy donor bank and an extensive gut microbiota sample database.

• “SmartMatch” Technology Platform:Leveraging advanced technologies such as metagenomics and metabolomics to deeply characterize patient microbiota profiles and intelligently match the most suitable healthy donor microbiota.

• “Intelligent Manufacturing” Standardized Products:Leveraging an advanced GMP-compliant manufacturing center, we achieve standardized, large-scale, and traceable production of various dosage forms, including bacterial suspensions and capsules, ensuring safety and efficacy. Its core product, "Liquid Live Probiotic Enteric-Coated Capsules," has demonstrated significant clinical value.

• "Closed-Loop" Ecosystem:Integrate the entire “screening–matching–preparation–delivery–administration–adjustment” chain to form a complete closed loop from diagnosis to treatment.

Like introducing a “navigator” and “repair agent” for precise regulation into the disordered microecological world, TreatGut’s technology platform is becoming a potential key to unlocking solutions for various refractory diseases.To date, its solutions have been implemented in clinical practice and research collaborations at multiple top-tier hospitals, cumulatively serving over 300,000 patients and demonstrating encouraging outcomes across various indications.

As an investor in this round, Kinghall Ventures possesses profound industry insights and extensive investment experience in the healthcare sector. Its decision to invest in TreatGut is driven by the following core rationale:

• Vast Blue Ocean Market:The global market for microbiome-based therapeutics holds immense potential, with urgent and unmet needs particularly in the management of chronic diseases and immune modulation. As a country with a large population, China presents an especially broad market prospect.

• Robust Technical Barriers:TreatGut has established significant technical barriers and first-mover advantages in precise microbiota matching, standardized preparation, and clinical translation, boasting a deep moat.

• Clear Business Path:The company has a clear pipeline layout, with core products having demonstrated efficacy in certain indications and actively expanding into new indications, ensuring a well-defined commercialization path.

• World-Class Team Strength:The founding team, combining top-tier scientific research backgrounds, extensive industry experience, and exceptional execution capabilities, is the key to leading industry development.

Hao Bixi, Managing Partner of Kinghall Venturesstated: “Microbiome intervention is one of the important development directions in future medicine. As a pioneer and leader in this field in China, TreatGut’s innovative PMT technology platform and its whole-industry-chain layout hold disruptive potential. We are optimistic about the company’s ability to address major clinical needs and look forward to its role in advancing the industrialization of microbiome-based healthcare, thereby benefiting a broader patient population.”

This round of comprehensive financing, exceeding RMB 100 million, has injected strong momentum into the development of TreatGut.Funds will be primarily used for:

• Deepening Core Platform Technologies:Continuously optimize precision matching algorithms to enhance preparation processes and automation levels.

• Accelerating Clinical Research and Registration:Advance large-scale, multi-center clinical trials of core products in key indications to accelerate the regulatory registration and filing processes both domestically and internationally.

• Expand Indication Portfolio:Exploring the Application Potential of PMT in Broader Fields, Including Enhancing Tumor Immunotherapy and Treating Neuropsychiatric Disorders.

• Enhance the commercialization network:Strengthen market education and channel development to facilitate the implementation and application of precision microbiome-based therapeutic solutions.

• Strengthening the Construction of Microbiome Banks and Databases: Further expand the scale of high-quality donor pools and microbiota data to solidify the R&D foundation.

The “hidden world” composed of trillions of microorganisms in the human gut holds new hope for disease treatment. Shanghai TreatGut, with its innovative “precision fecal microbiota transplantation” technology, has effectively grasped the key to unlocking this treasure trove.Kinghall Ventures’ strategic investment not only affirms its past achievements but also serves as a strong endorsement of its vision to reshape the future trillion-dollar microecological healthcare landscape.

As precision medicine extends its reach into the microscopic universe of the gut microbiota, TreatGut is leading a quiet yet potentially profound medical revolution. We look forward to this precisely regulated “micro-ecological engine” bringing new hope for cure to more patients suffering from diseases.